Triazolo[3,4-b]thiadiazoles are a class of heterocyclic compounds, which have attracted great interest in medicinal chemistry owing to their wide range of pharmacological activities. A number of triazoles fused to thiadiazoles are incorporated into a wide variety of therapeutically important compounds possessing a broad spectrum of biological activities. Considering such a significant pharmacological potential, as well as wide synthetic possibilities triazolo-thiadiazoles have received considerable attention from scientific community and are extensively used for construction of prospective drug-likes molecules. In this review, we summarized the literature data about the main synthetic approaches for obtaining condensed heterocyclic compounds based on triazolo[3,4-b][1,3,4]thiadiazole scaffold as promising objects for modern bioorganic and medicinal chemistry.

A series of some new (E)-2-(arylbenzylidene)-2-((4-methoxyphenyl)amino)acetohydrazides 4(a-j) have been conveniently synthesized by intermolecular oxidative cyclization of (E)-2-(arylbenzylidene)-2-[(4-methoxyphenyl)amino]acetohydrazides promoted by iodobenzene diacetate as an oxidant. The structures of the synthesized compounds have been confirmed by 1H NMR, IR, MS and elemental analysis. All the synthesized compounds were tested for their inhibitory action against clinically isolated strains i.e., Bacillus subtilis, Staphylococcus aureus, Xanthomonas campestris, Escherichia coli and Fusarium oxysporum. Compounds 4f (21-28 mm, 73.8 %), 4i (20-24 mm, 72.4 %) and 4j (21-27 mm, 71.6 %) demonstrated good antimicrobial activity against all the tested bacterial and fungal strains.